ly increases with rising levels of GSH but starts to decline when the ratio of GSH to Cr(VI) exceeds 10:1.
The production of the heavy metal-binding proteins, metallothionein (MT)-I and MT-II, is induced by heavy metals such as Zn and Cd (Hamer, 1986; Kägi and Schäffer, 1988) . There are four types of MTs in mammalians, namely MT-I, MT-II, MT-III and MT-IV. The expression of MT-I and MT-II is heavy metal inducible and ubiquitous while MT-III and MT-IV are tissue specific and only weakly stress-inducible. MT-I and MT-II induction maintains Zn homeostasis (Dalton et al., 1996; Kelly et al., 1996) and affords protection against toxic heavy metals by sequestering them and lowering their concentrations at critical intracellular sites (Michalska and Choo, 1993; Masters et al., 1994; Klaassen and Liu, 1998) . MT-I and MT-II are important molecules in the cellular self-defense system and their cysteine residues have been reported to scavenge ROS (Thornalley and Vasák, 1985) . Although MT-I and MT-II cannot bind chromium, it can act as a protective factor against Cr(VI)-induced DNA lesions by scavenging ROS and reducing Cr(VI) directly to Cr(III), thereby eliminating the formation of toxic intermediate forms. However, Cr(VI) has been known to inhibit MT-I and MT-II transcription, which may play a role in the carcinogenicity of Cr(VI). Thus, it is important to understand the mechanism by which Cr(VI) inhibits MT-I transcription to understand the carcinogenicity of Cr(VI).
MT-I and MT-II expression is induced by Zn and Cd via the metal response element-binding transcription factor-1 (MTF-1) (Radtke et al., 1993; Brugnera et al., 1994; Otsuka et al., 1994; Wang et al., 2004) . MTF-1 contains six Cys 2 His 2 zinc fingers and three transactivation domains. These six zinc fingers and their linker peptides are structurally and functionally heterogeneous and play an essential role in its metalloregulatory function (Koizumi et al., 2000; Jiang et al., 2003; Li et al., 2006) . Two research groups have reported that Cr(VI) prevents metal-dependent MT-1 and MT-II induction (Alcedo et al., 1994; Majumder et al., 2003) . In particular, Majumder et al. (2003) showed that overexpression of MTF-1 blocks the inhibitory effects of Cr(VI) and concluded that Cr(VI) suppresses MTF-1 and inhibits MT-1 and MT-II gene expression mediated by metal-dependent MTF-1. Previously, we had reported that a complex is formed between MTF-1 and p300 in response to Zn or Cd exposure (Li et al., 2006) . Cr(VI) inhibits the Zn-induced formation of this MTF-1-p300 transcription factor complex, leading to a failure to recruit polymerase II to the mouse MT-I gene . Cr(VI) is also known to affect the expression of other genes besides MT-I and MT-II. For example, it upregulates the expression of Bcl-2 and the urokinase-type plasminogen receptor (Ceryak et al., 2004) , in the latter case, by increasing the stability of its mRNA. Cr(VI) also downregulates the expression of a diverse set of genes including those encoding CYP1A1 (Wei et al., 2004) , phosphoenolpyruvate carboxykinase Wetterhahn et al., 1989) , and interleukin-8 (Shumilla et al., 1999) . Cr(VI) inhibits the transcription of polycyclic aromatic hydrocarbon (PAH)-inducible promoters by cross-linking HDAC1-DNA methyltransferase 1 complexes to the CYP1A1 chromatin (Schnekenburger et al., 2007) (thus blocking the release of histone deacetylase (HDAC)). Although reports suggest that Cr(V), Cr(IV), and ROS may be key factors in the modification of cellular gene expression, the detailed mechanism by which Cr(VI) affects gene expression has not been completely understood. In the present study, we have shown that Cr(VI) inhibits mouse MT-1 transcription via an HDAC-independent mechanism and by modifying the HAT-independent transactivation potential of p300 under our experimental conditions.
MATERIALS AND METHODS

Cell culture and transfection
Mouse embryo fibroblast (MEF) cells prepared from wild-type (WT) mice and MTF-knock out (MTF-KO) mice were cultured in Dulbecco's modified Eagle's medium (DMEM) -4.5 g/l glucose and supplemented with 10% fetal bovine serum (FBS), as described previously . The previously described MTF-1 expression plasmid, pRc/CMV-MTF-1, (Kimura et al., 2004) , and p300 expression plasmid pCMVβ-p300-HA, which was purchased from Millipore (Billerica, MA, USA), were used for overexpression of MTF-1 and p300, respectively. The empty expression plasmid pRc/CMV was used for the control group. Cells were plated in 12-well plates and transfected at 70-80% confluence using FuGENE 6 according to the manufacturer's protocol (Roche Diagnostics, Basel, Switzerland). Briefly, 3 μl of FuGENE 6 was diluted with 100 μl of serum-and antibiotic-free Opti-MEM medium (Life Technologies, Carlsbad, CA, USA). Then, 1.0 μg of plasmid DNA was added and the mixture was incubated for 15 min. The FuGENE 6:DNA complex remained on the cells for 24 hr.
Luciferase reporter assay
The reporter plasmid pGL4.12-MT-264/+42, used for the luciferase reporter assay, contained the mouse MT-I promoter spanning bases -264 to +42(relative to the tran-scription start site). The promoter construct was cloned into pGL4.12[luc2CP] as previously described (Kimura et al., 2002) .
For the luciferase reporter assay, 0.25 μg of the reporter plasmid pGL4.12-MT-264/+42, 0.25 ng of the control Renilla reporter plasmid, pRL-SV40, and 0.75 μg of the expression plasmid were used as plasmid DNA. Co-transfection of pRL-SV40 was done for the normalization of transfection efficiency. The FuGENE 6:DNA complex remained on the cells for 24 hr. For the luciferase assay, cells were lysed using 1 × Passive Lysis Buffer (Promega, Madison, WI, USA), following which firefly luciferase activity of the reporter plasmid and Renilla luciferase activity of the control plasmid were measured with the Dual-Luciferase Reporter Assay System (Promega) in a luminometer (GloMax™ 20/20n Luminometer; Promega). The firefly luciferase activity was normalized to the Renilla luciferase activity.
Western blotting
Whole-cell extracts from cultured cells were prepared as described previously . Proteins in the whole-cell extract were separated on SDS-PAGE gel and analyzed by Western blotting using polyclonal antibody against MTF-1 (Santa Cruz, CA, USA), polyclonal antibody against p300 (Santa Cruz), monoclonal antibody against HA-tag (clone 3F10: Roche, Basel, Switzerland) and monoclonal antibody against β-actin (clone AC-15: Sigma, St. Louis, MO, USA).
Preparation of total RNA and quantitative reverse transcription-PCR
Total RNA was isolated from cultured cells using Isogen (Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol. Reverse transcription was carried out with random hexamers and a PrimeScript RT reagent kit (Takara Bio Inc., Shiga, Japan). Quantitative PCR was carried out with TaqMan Gene Expression Assays (Life Technologies) for mouse MT-I (assay ID: Mm00496660_ g1) and Premix ExTaq (Takara Bio). To normalize the amount of RNA and to achieve efficient reverse transcription, the amount of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was measured using a Mouse GAPD Endogenous Control (Life Technologies). Trichostatin A (TSA), an HDAC inhibitor, was added to the culture medium 16 hr prior to the addition of Cr(VI) and Zn.
In vitro HAT assay
The effects of metals on the HAT activity of p300 were measured using a fluorescent method with the HAT Assay Kit (Fluorescent) according to the manufacturer's protocol (Active Motif, Carlsbad, CA, USA). Recombinant p300 and anacardic acid were provided with the assay kit. Histone H3 peptide was used as the substrate and anacardic acid, a p300 HAT inhibitor, served as a positive control.
RESULTS
Overexpression of MTF-1 and p300 counteracted the inhibitory effects of Cr(VI)
First, we examined the effects of overexpression of MTF-1 and p300 on Zn-induced MT-I promoter activation in MEF cells. Zn-induced MT-I promoter activation was observed not only in the control group that was transfected with the empty expression plasmid, but also in the WT groups overexpressing MTF-1 and p300 (Fig. 1A) . Cr(VI) inhibited this Zn-induced MT-I promoter activation, and this inhibition was partially overcome by the overexpression of MTF-1 and p300. Comparing MT-1 promoter activity after treatment with Cr(VI) and Zn in each group revealed 43% of MT-1 promoter activity in the control group, 59% in the MTF-1-overexpressing group, and 73% in the p300-overexpressing group.
Next, we examined the effects of Cr(VI) on endogenous MT-I gene transcription after co-transfection of different expression plasmids by using MTF-1 KO MEF cells and by measuring MT-1 mRNA levels. All cells were transfected with the MTF-1 expression plasmid (as plasmid 1). The respective expression plasmids (control, MTF-1, or p300 in an amount that was nine times that of plasmid 1) were co-transfected along with the MTF-1 expression plasmid (as plasmid 2). The expression levels of MTF-1 and HA-tagged p300 protein after the transfection were measured by Western blotting (Fig. 1C) . MTF-1 protein levels were increased in the MTF-1 expression plasmid-dependent manner. The results show that 100 μM of Cr(VI) inhibited the induction of MT-I gene transcription in the control group as well as in the MTF-1-and p300-overexpressing groups (Fig. 1B) . In contrast, only the p300-overexpressing group showed no significant difference in the MT-1 mRNA levels after treatment with Zn and Zn plus 50 μM Cr(VI).
Trichostatin A could not block the inhibitory effect of Cr(VI) on MT-1 transcription
It has been reported that Cr(VI) inhibits transcription from nuclear factor-κB (NF-κB) and PAH-inducible promoters by blocking the release of HDAC (Shumilla et al., 1999; Wei et al., 2004) . As HAT activity of p300 is often involved in the release of HDAC from an active promoter (Schmeck et al., 2008) , we hypothesized , and with the empty expression vector pRc/CMV (control group), or the expression vectors pRc/CMV-MTF-1 (MTF-1) or pCMVβ-p300-HA (p300). Transfected cells were cultured for 24 hr and then incubated with 50 μM Cr(VI) for 3 hr prior to the addition of 100 μM Zn. Whole-cell lysates were prepared 6 hr after Zn addition and reporter gene expression was measured using the Dual-Luciferase Reporter Assay System. (B) MTF-1 knockout (KO) MEF cells were transfected with the empty expression vector, pRc/CMV, or the expression vectors pRc/CMV-MTF-1 or pCMVβ-p300-HA. Sixteen hours later, these overexpressed cells were incubated with 50 or 100 μM Cr(VI) for 3 hr prior to the addition of the indicated concentration of Zn (100 μM). Total RNA was isolated 6 hr after Zn addition and MT-I and GAPDH mRNAs were then reverse-transcribed and measured by quantitative real-time PCR using a TaqMan probe. The relative amounts of MT-I mRNA were determined by calculating the ratio between the amounts of MT-I mRNA and the mRNA of the housekeeping gene, GAPDH. Values are expressed as the mean ± S.D. of three independent experiments. (C) Whole-cell extracts from MTF-1 KO MEF cells were prepared 24 hr after transfection and analyzed by Western blotting using indicated antibodies. Western blotting with the anti-β-actin antibody was used to confirm that nearly equal amounts of each protein were present in the extracts. (A) *, significantly different from the untreated control (P < 0.05); (B) †, significantly different from zinc-treated alone (P < 0.05).
that the inhibition of transcription by Cr(VI) would inhibit the HAT activity of p300. To determine the extent of involvement of the inhibition of p300 HAT activity in the inhibition of MT-1 transcription by Cr(VI), MT-I mRNA levels were measured after treatment with Zn or Zn and Cr(VI), both without any and after treatment with TSA. Our results show that TSA increased MT-I mRNA levels in both untreated and Zn-treated groups in comparison to the TSA-untreated groups, but not in the group treated with Cr(VI) and Zn (Fig. 2) . Thus, our data indicate that TSA could not block the inhibitory effects of Cr(VI) on MT-1 transcription.
Effects of Cr(III), Cr(VI), and Zn on HAT activity
In vitro effects of heavy metals on HAT activity were examined to clarify the mechanism of inhibition of Zninduced MT-I transcription by Cr(VI). Interestingly, p300 is an essential factor for Zn-induced MT-I transcription, and Cr(VI) has been reported to inhibit the formation of a complex containing p300 and MTF-1. However, our results show that Cr(VI) did not have any remarkable effects on the HAT activity of p300 (Fig. 3) . Although Zn also did not affect HAT activity, 10 μM Cr(III) was found to significantly increase HAT activity. MEF cells were incubated with 250 nM TSA for 16 hr prior to the addition of 100 μM Cr(VI) for 3 hr. Cells were then treated with 100 μM Zn. Total RNA was isolated 6 hr after Zn addition and MT-I and GAPDH mRNAs were reverse-transcribed and measured by real-time PCR using a TaqMan probe. Values are expressed as the mean ± S.D. *, significantly different from metal-untreated control (P < 0.05); †, significantly different from zinctreated alone (P < 0.05); ¶ , significantly different from the TSA-untreated group (P < 0.05).
Fig. 3. Effects of Cr(III), Cr(VI)
, and Zn on HAT activity of p300. Recombinant p300 catalytic domain was incubated with acetylCoA, histone H3 peptide, and the indicated heavy metals. After incubation, the CoA-SH generated was detected on the basis of its free sulfhydryl groups. Values are expressed as the mean ± S.D. *, significantly different from metal-or anacardic acid-untreated control (P < 0.05).
DISCUSSION
Cr(VI) is known to inhibit MT-1 gene transcription (Alcedo et al., 1994; Majumder et al., 2003) . Our study shows that p300 is a target in the Cr(VI) inhibition of MT-I transcription as the HAT-independent transactivation potential of p300 was modified. Using in vivo footprinting, Majumder et al. (2003) revealed that basal and inducible binding of MTF-1 to MRE are not affected by treatment with Cr(VI). Previously, we had shown that Cr(VI) inhibited the formation of the MTF-1-p300 complex , which is a critical step for Zn-induced MT-I transcription . However, it is still unclear whether the inhibition by Cr(VI) is through its effects on MTF-1 or p300. To clarify the target of Cr(VI), we examined the effects of overexpression of MTF-1 and p300 on MT-I promoter activity and endogenous MT-I transcription. We found that overexpression of both MTF-1 and p300 could overcome the inhibitory effects of Cr(VI) (Fig. 1) . As mentioned previously, Majumder et al. (2003) showed that overexpression of MTF-1 blocks the inhibitory effects of Cr(VI) and concluded that Cr(VI) inhibits MT-1 gene expression by suppressing MTF-1. The inhibitory mechanisms of Cr(VI) might be complicated. Both MTF-1 and p300 appear to be targets for the inhibition by Cr(VI) because the inhibition was partially overcome by the overexpression of MTF-1 and p300 separately. The mechanism by which the overexpression of either MTF-1 or p300 overcomes the inhibitory effects of Cr(VI) is not clear. Comparing the remaining activity in the Cr(VI) and Zn-treated group against the Zn-treated group, the value in p300-overexpressing cells was much higher than that of the controland MTF-1-overexpressing cells (Fig. 1A) . Furthermore, only the p300-overexpressing group showed no significant difference in the MT-1 mRNA levels after treatment with Zn and Zn plus 50 μM Cr(VI) (Fig. 1B) . The effect of MTF-1 and p300-overexpression is subtle, but it seems that p300-overexpression is more effective than MTF-1 overexpression in the attenuation of the inhibition of MT-1 promoter activation by Cr(VI). In this study, we focused on the mechanisms by which p300 overexpression overcame the inhibitory effects of Cr(VI). Wei et al. (2004) have reported that Cr(VI) blocks p300 recruitment to the CYP1A1 promoter and cross-links HDAC1-DNA methyltransferase 1 complexes to the CYP1A1 chromatin (Schnekenburger et al., 2007) . Thus, Cr(VI) prevents the opening up of the CYP1A1 chromatin structure. We used TSA, an HDAC inhibitor, to clarify the involvement of HDAC1 in the inhibition of MT-I transcription via a possible cross-linking of HDAC1 and DNA. It has already been reported that TSA decreases the association of HDAC1 with the methylated MT-I promoter in mouse lymphosarcoma cells (Ghoshal et al., 2002) . Hence, we hypothesized that TSA would be able to block the inhibitory effects of Cr(VI) if HDAC1 was involved in the Cr(VI)-mediated inhibition of MT-I transcription (Fig. 2) . However, our results show that TSA could not block the inhibitory effects of Cr(VI), suggesting that Cr(VI) inhibits MT-I transcription by an HDAC-independent mechanism. Hence, our results indicate that inhibition by Cr(VI) was probably due to its inhibitory effects on the HATdependent or -independent transactivation of MT-I transcription by p300 rather than preventing the release of HDAC from the MT-I promoter.
To further study the effects of the inhibition by Cr(VI) on the transactivation ability of p300, we examined the effects of Cr(VI) on p300 HAT activity. Classically, acetylation of histones H3 and H4 in chromatin causes an opening of the chromatin structure because of the decrease in positive charge on the histones and the consequent decrease in interaction of these histones with the negatively charged DNA (Sterner and Berger, 2000) . Once the chromatin structure opens up around a gene promoter, transcription from that gene will be accelerated (Gregory et al., 1998; Utley et al., 1998; Sterner and Berger, 2000) . Hence, as reported by others, an inhibitor of HAT silences transcription from various promoters by inhibiting the acetylation of histones and consequently, preventing the opening up of the chromatin structure around those promoters (Lau et al., 2000; Balasubramanyam et al., 2003; Cebrat et al., 2003) . Cr(VI) enters cells via the sulfate anion transporter system (Alexander and Aaseth, 1995) and is reduced to intermediate oxidation states, such as Cr(V) and Cr(IV), in the process of forming stable Cr(III) forms. In this study, we showed that there were no in vitro inhibitory effects of 0.4 to 50 μM Cr(VI) or of Cr(III) on p300 HAT activity (Fig. 3) . Indeed, 10 μM Cr(III) was seen to activate p300 HAT activity. As reported by others, p300 is a co-activator which is necessary for the transcription of many genes because it both acts as a HAT and, in a HATindependent role, serves as an adapter between a multitude of transcription factors and the basal transcriptional machinery (Chan and La Thangue, 2001) . Cr(VI) has been reported to decrease the interaction of p65 with p300 and cAMP-responsive-element-binding protein-binding protein (CBP) (Shumilla et al., 1999; Wei et al., 2004) Our results demonstrate that Cr(VI) and Cr(III) did not inhibit HAT activity, thus suggesting that Cr(VI) interfered with the HAT-independent adapter function of p300.
In summary, our previous study had shown that Cr(VI) impairs the activation of MT-1 gene expression by MTF-1 in response to Zn by inhibiting the formation of an MTF-1-p300 transcription factor complex. The results of the present study demonstrate that Cr(VI) interferes with the HAT-independent adapter function of p300. Further studies will address the question of whether Cr(VI)-mediated inhibition of MT-1 transcription exacerbates the process of malignant transformation and whether MT-1 acts as a protective factor against Cr(VI)-induced malignant transformation.
